These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 22120913

  • 1. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE, SWiTCH Study Investigators.
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [Abstract] [Full Text] [Related]

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 3. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE, Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [Abstract] [Full Text] [Related]

  • 4. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE, TWiTCH Investigators.
    Am J Hematol; 2015 Sep; 90(9):806-10. PubMed ID: 26087998
    [Abstract] [Full Text] [Related]

  • 5. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, Davis BR, Ware RE, TWiTCH Investigators.
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [Abstract] [Full Text] [Related]

  • 6. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E, Kaya B, Gadong N, Hemmaway C, Newell H, Simmons A, Whitmarsh S, Telfer P.
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [Abstract] [Full Text] [Related]

  • 8. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A, Ware RE, Thornburg CD.
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [Abstract] [Full Text] [Related]

  • 9. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [Abstract] [Full Text] [Related]

  • 10. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A, Musallam KM, Wood JC, Sheikh-Taha M, Daou L, Taher AT.
    Eur J Haematol; 2009 Dec 01; 83(6):565-71. PubMed ID: 19737308
    [Abstract] [Full Text] [Related]

  • 11. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Dec 01; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 12. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
    Stanley HM, Friedman DF, Webb J, Kwiatkowski JL.
    Pediatr Blood Cancer; 2016 Aug 01; 63(8):1414-8. PubMed ID: 27100139
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 14. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
    Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA.
    Br J Haematol; 2016 Nov 04; 175(4):705-713. PubMed ID: 27507431
    [Abstract] [Full Text] [Related]

  • 15. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
    Brown K, Subramony C, May W, Megason G, Liu H, Bishop P, Walker T, Nowicki MJ.
    J Pediatr Hematol Oncol; 2009 May 04; 31(5):309-12. PubMed ID: 19415007
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec 04; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 17. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A.
    Eur J Haematol; 2017 Mar 04; 98(3):280-288. PubMed ID: 27859648
    [Abstract] [Full Text] [Related]

  • 18. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Mar 04; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 19. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH.
    J Pediatr; 2004 Sep 04; 145(3):346-52. PubMed ID: 15343189
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M, Ou P, Elie C, Canniffe C, Kutty S, Delos V, Graffigne C, de Montalembert M, Brousse V.
    J Pediatr Hematol Oncol; 2016 Oct 04; 38(7):497-502. PubMed ID: 27548334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.